Saranac Partners Ltd Sells 589,836 Shares of AbbVie Inc. $ABBV

Saranac Partners Ltd cut its holdings in AbbVie Inc. (NYSE:ABBV) by 93.8% in the fourth quarter, HoldingsChannel reports. The firm owned 39,243 shares of the company’s stock after selling 589,836 shares during the period. AbbVie accounts for approximately 3.5% of Saranac Partners Ltd’s portfolio, making the stock its 7th biggest holding. Saranac Partners Ltd’s holdings in AbbVie were worth $8,979,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Larson Financial Group LLC boosted its holdings in AbbVie by 10.9% in the fourth quarter. Larson Financial Group LLC now owns 29,114 shares of the company’s stock worth $6,652,000 after purchasing an additional 2,858 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in AbbVie by 4.1% in the fourth quarter. Handelsbanken Fonder AB now owns 1,318,889 shares of the company’s stock worth $301,353,000 after purchasing an additional 52,526 shares in the last quarter. Csenge Advisory Group boosted its holdings in AbbVie by 56.1% in the fourth quarter. Csenge Advisory Group now owns 36,108 shares of the company’s stock worth $8,250,000 after purchasing an additional 12,983 shares in the last quarter. Integral Investment Advisors Inc. boosted its holdings in AbbVie by 52.0% during the fourth quarter. Integral Investment Advisors Inc. now owns 2,473 shares of the company’s stock valued at $565,000 after acquiring an additional 846 shares during the period. Finally, Aviance Capital Partners LLC boosted its holdings in AbbVie by 0.3% during the fourth quarter. Aviance Capital Partners LLC now owns 145,158 shares of the company’s stock valued at $33,167,000 after acquiring an additional 388 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Insider Activity

In related news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.06% of the company’s stock.

AbbVie Stock Performance

NYSE ABBV opened at $213.77 on Wednesday. AbbVie Inc. has a twelve month low of $180.25 and a twelve month high of $244.81. The stock has a market cap of $377.69 billion, a PE ratio of 105.31, a PEG ratio of 0.72 and a beta of 0.32. The firm has a 50-day simple moving average of $209.49 and a 200 day simple moving average of $219.84.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the prior year, the business posted $2.46 earnings per share. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. Research analysts forecast that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend was Wednesday, April 15th. AbbVie’s dividend payout ratio is 340.89%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ABBV. Berenberg Bank set a $275.00 price target on shares of AbbVie in a report on Tuesday, January 20th. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Citigroup decreased their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. Cantor Fitzgerald restated an “overweight” rating and set a $240.00 price target on shares of AbbVie in a report on Thursday, April 30th. Finally, Barclays began coverage on shares of AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $253.43.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s neuroscience drugs boosted Q1 sales growth, with neuroscience revenue rising 26% year over year thanks to Vraylar, migraine treatments and Botox, signaling continued strength in a key growth area. Here’s How Neuroscience Drugs Boost AbbVie’s Q1 Sales Growth
• Positive Sentiment: AbbVie was highlighted in valuation-focused articles as potentially undervalued, which can support the stock by drawing attention to its earnings and dividend appeal. 3 Stocks That May Be Priced Below Their Estimated Value In May 2026
• Neutral Sentiment: AbbVie was listed among trending stocks after increased user interest on Zacks, but the coverage did not point to a new material catalyst by itself. Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
• Neutral Sentiment: Evercore ISI slightly lowered its price target on AbbVie to $235 from $236, which is a small adjustment and not a major negative signal for the stock. AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI
• Negative Sentiment: Broader pharmaceutical-policy headlines about Trump’s drug-pricing push could weigh on the sector, since lower Medicare pricing would pressure pharma margins and sentiment. Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.